Immunomodulation by intravenous omega‐3 fatty acid treatment in older subjects hospitalized for COVID‐19: A single‐blind randomized controlled trial

Arnardottir, Hildur; Pawelzik, Sven-Christian; Sarajlic, Philip; Quaranta, Alessandro; Kolmert, Johan; Religa, Dorota; Wheelock, Craig E.; Bäck, Magnus

doi:10.1002/ctm2.895

Cited by 21 publications

(31 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study protocol is registered at clinicaltrials.gov with reference NCT04647604 has been published [ 18 ]. The primary endpoint measures have been reported [ 12 ].…”

Section: Methodsmentioning

confidence: 99%

“…The IMPRECOVID study revealed specific plasma oxylipid profiles to distinguish COVID-19-associated pneumonia requiring intensive care [ 11 ]. The randomized controlled single-blind COVID-Omega-F trial showed that intravenous n-3 PUFA administration shifted the plasma lipid signature of COVID-19 towards increased proresolving precursor levels and decreased leukotoxin diols [ 12 ]. While these plasma analyses provide a snapshot of lipid metabolism in COVID-19, the urinary oxylipidome gives a more complete picture of time-integrated chemically stable metabolites that reflects systemic biosynthesis [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

“…The beneficial immune responses after n-3 PUFA administration in the COVID-Omega-F trial included decreased neutrophil to lymphocyte ratio, preserved leukocyte phagocytic capacity, decreased immunothrombosis and preserved interferon-response [ 12 ]. The recent VASCEPA-COVID-19 CardioLink-9 trial showed that oral n-3 PUFA treatment with the EPA ethyl ester icosapent ethyl for 14 days improves symptoms and reduces C-reactive protein (CRP) in ambulatory COVID-19 patients [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Decreased oxidative stress and altered urinary oxylipidome by intravenous omega-3 fatty acid emulsion in a randomized controlled trial of older subjects hospitalized for COVID-19

Pawelzik

Arnardottir

Sarajlic

et al. 2023

Free Radical Biology and Medicine

Self Cite

View full text Add to dashboard Cite

“…The study protocol is registered at clinicaltrials.gov with reference NCT04647604 has been published [ 18 ]. The primary endpoint measures have been reported [ 12 ].…”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Decreased oxidative stress and altered urinary oxylipidome by intravenous omega-3 fatty acid emulsion in a randomized controlled trial of older subjects hospitalized for COVID-19

Pawelzik

Arnardottir

Sarajlic

et al. 2023

Free Radical Biology and Medicine

Self Cite

View full text Add to dashboard Cite

“…Resolvins such as the E series from eicosapentaenoic acid (EPA), D series from docosahexaenoic acid (DHA), and T series from docosapentaenoic acid (DPA) are synthesized from essential omega-3 fatty acids by corresponding enzymes such as epoxidase and lipoxidase [ 13 , 14 ]. Omega-3 fatty acid has been proved to be effective in treating COVID-19 [ 15 ], cardiovascular diseases [ 16 ], cognitive impairment [ 17 ], rheumatoid arthritis [ 18 ], and other complex diseases through an immune regulation. The actions of resolvins in the inflammatory response mainly include reducing the PMN inflammatory infiltration [ 19 , 20 , 21 , 22 ], decreasing inflammatory factors [ 23 , 24 , 25 , 26 , 27 , 28 ], improving inflammatory pain and preventing a central sensitization [ 29 ].…”

Section: Introductionmentioning

confidence: 99%

Roles of Resolvins in Chronic Inflammatory Response

Liu

Fan

Liu

et al. 2022

IJMS

View full text Add to dashboard Cite

An inflammatory response is beneficial to the organism, while an excessive uncontrolled inflammatory response can lead to the nonspecific killing of tissue cells. Therefore, promoting the resolution of inflammation is an important mechanism for protecting an organism suffering from chronic inflammatory diseases. Resolvins are a series of endogenous lipid mediums and have the functions of inhibiting a leukocyte infiltration, increasing macrophagocyte phagocytosis, regulating cytokines, and alleviating inflammatory pain. By promoting the inflammation resolution, resolvins play an irreplaceable role throughout the pathological process of some joint inflammation, neuroinflammation, vascular inflammation, and tissue inflammation. Although a large number of experiments have been conducted to study different subtypes of resolvins in different directions, the differences in the action targets between the different subtypes are rarely compared. Hence, this paper reviews the generation of resolvins, the characteristics of resolvins, and the actions of resolvins under a chronic inflammatory response and clinical translation of resolvins for the treatment of chronic inflammatory diseases.

show abstract

“…A hyperinflammatory response has been associated with COVID-19 in increasing the risk of thrombosis [9]. The inflammatory disease process, prolonged hospitalization, and preexisting comorbidities can all contribute to the aggressive thrombotic burden in patients with thrombosis [10][11][12][13]. A study in two Dutch university hospitals and one Dutch teaching hospital showed a 31% incidence of thrombotic complications in patients in the intensive care unit (ICU) with COVID-19 [14].…”

Section: Introductionmentioning

confidence: 99%

Characterizing Thrombotic Complication Risk Factors Associated With COVID-19 via Heterogeneous Patient Data: Retrospective Observational Study

et al. 2022

View full text Add to dashboard Cite

Background COVID-19 has been observed to be associated with venous and arterial thrombosis. The inflammatory disease prolongs hospitalization, and preexisting comorbidities can intensity the thrombotic burden in patients with COVID-19. However, venous thromboembolism, arterial thrombosis, and other vascular complications may go unnoticed in critical care settings. Early risk stratification is paramount in the COVID-19 patient population for proactive monitoring of thrombotic complications. Objective The aim of this exploratory research was to characterize thrombotic complication risk factors associated with COVID-19 using information from electronic health record (EHR) and insurance claims databases. The goal is to develop an approach for analysis using real-world data evidence that can be generalized to characterize thrombotic complications and additional conditions in other clinical settings as well, such as pneumonia or acute respiratory distress syndrome in COVID-19 patients or in the intensive care unit. Methods We extracted deidentified patient data from the insurance claims database IBM MarketScan, and formulated hypotheses on thrombotic complications in patients with COVID-19 with respect to patient demographic and clinical factors using logistic regression. The hypotheses were then verified with analysis of deidentified patient data from the Research Patient Data Registry (RPDR) Mass General Brigham (MGB) patient EHR database. Data were analyzed according to odds ratios, 95% CIs, and P values. Results The analysis identified significant predictors (P<.001) for thrombotic complications in 184,831 COVID-19 patients out of the millions of records from IBM MarketScan and the MGB RPDR. With respect to age groups, patients 60 years and older had higher odds (4.866 in MarketScan and 6.357 in RPDR) to have thrombotic complications than those under 60 years old. In terms of gender, men were more likely (odds ratio of 1.245 in MarketScan and 1.693 in RPDR) to have thrombotic complications than women. Among the preexisting comorbidities, patients with heart disease, cerebrovascular diseases, hypertension, and personal history of thrombosis all had significantly higher odds of developing a thrombotic complication. Cancer and obesity were also associated with odds>1. The results from RPDR validated the IBM MarketScan findings, as they were largely consistent and afford mutual enrichment. Conclusions The analysis approach adopted in this study can work across heterogeneous databases from diverse organizations and thus facilitates collaboration. Searching through millions of patient records, the analysis helped to identify factors influencing a phenotype. Use of thrombotic complications in COVID-19 patients represents only a case study; however, the same design can be used across other disease areas by extracting corresponding disease-specific patient data from available databases.

show abstract

Immunomodulation by intravenous omega‐3 fatty acid treatment in older subjects hospitalized for COVID‐19: A single‐blind randomized controlled trial

Cited by 21 publications

References 10 publications

Decreased oxidative stress and altered urinary oxylipidome by intravenous omega-3 fatty acid emulsion in a randomized controlled trial of older subjects hospitalized for COVID-19

Decreased oxidative stress and altered urinary oxylipidome by intravenous omega-3 fatty acid emulsion in a randomized controlled trial of older subjects hospitalized for COVID-19

Roles of Resolvins in Chronic Inflammatory Response

Characterizing Thrombotic Complication Risk Factors Associated With COVID-19 via Heterogeneous Patient Data: Retrospective Observational Study

Contact Info

Product

Resources

About